Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Posaconazole in Pediatric Participants With Invasive Aspergillosis
2019-002267-10Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of posaconazole in invasive aspergillosis (IA) and aspergillosis, sponsored by Merck & Co. Primary endpoint: Treatment-related adverse events. Started Oct 2019; status: completed.
02
Drugs
posaconazole
03
Conditions
invasive aspergillosis (IA)aspergillosis
Beyond the preview
Go deeper on 2019-002267-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002267-10.